Enbioco인바이오
352940 · KOSDAQ · ₩352940 · 인바이오
₩1,884▼ ₩17 (0.89%)End-of-day · Oct 29, 2026 · End-of-day prices.
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | ₩34B | ₩36B | ₩34B | ₩34B | ₩33B |
| Cost of sales | ₩22B | ₩24B | ₩27B | ₩28B | ₩22B |
| Gross profit | ₩12B | ₩12B | ₩7.2B | ₩6.6B | ₩11B |
| Operating income | ₩917M | ₩1.4B | −₩3.4B | −₩4.8B | ₩1.1B |
| Net income | ₩1B | ₩646M | −₩6.3B | −₩3.4B | ₩5.2B |
| Net income to shareholders | ₩1B | ₩646M | −₩6.3B | −₩3.4B | ₩5.2B |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Total assets | ₩69B | ₩68B | ₩66B | ₩87B | ₩91B |
| Current assets | ₩36B | ₩40B | ₩47B | ₩68B | ₩71B |
| Cash and equivalents | ₩2.9B | ₩938M | ₩2.9B | ₩11B | ₩22B |
| Total liabilities | ₩27B | ₩26B | ₩26B | ₩41B | ₩41B |
| Current liabilities | ₩22B | ₩22B | ₩25B | ₩39B | ₩38B |
| Borrowings | ₩13B | ₩14B | ₩12B | ₩22B | ₩20B |
| Total equity | ₩42B | ₩41B | ₩41B | ₩46B | ₩50B |
| Shareholders' equity | ₩42B | ₩41B | ₩41B | ₩46B | ₩50B |
Cash flow
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash from operations | ₩9.1B | ₩4.9B | ₩11B | −₩8.5B | −₩2.3B |
| Capital spending | −₩6.8B | ₩8.7B | ₩155M | ₩180M | ₩484M |
| Free cash flow | ₩2.3B | −₩3.8B | ₩11B | −₩8.7B | −₩2.8B |
Consolidated where available. Amounts in won.
Also known as: Enbioco / 인바이오 / 352940 / KRX:352940
Source: KRX statistical information